These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22934745)

  • 1. Role of formyl peptide receptors (FPR) in abnormal inflammation responses involved in neurodegenerative diseases.
    Mollica A; Stefanucci A; Costante R; Pinnen F
    Antiinflamm Antiallergy Agents Med Chem; 2012; 11(1):20-36. PubMed ID: 22934745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection from complement-mediated inflammatory damage.
    Kulkarni AP; Kellaway LA; Lahiri DK; Kotwal GJ
    Ann N Y Acad Sci; 2004 Dec; 1035():147-64. PubMed ID: 15681806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease.
    Klegeris A; McGeer PL
    Curr Alzheimer Res; 2005 Jul; 2(3):355-65. PubMed ID: 15974901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural products as a potential modulator of microglial polarization in neurodegenerative diseases.
    Jin X; Liu MY; Zhang DF; Zhong X; Du K; Qian P; Gao H; Wei MJ
    Pharmacol Res; 2019 Jul; 145():104253. PubMed ID: 31059788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microglial activation and its implications in the brain diseases.
    Dheen ST; Kaur C; Ling EA
    Curr Med Chem; 2007; 14(11):1189-97. PubMed ID: 17504139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches.
    Van Eldik LJ; Thompson WL; Ralay Ranaivo H; Behanna HA; Martin Watterson D
    Int Rev Neurobiol; 2007; 82():277-96. PubMed ID: 17678967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs to Treat Neuroinflammation in Neurodegenerative Disorders.
    Wang YC; Kung WM; Chung YH; Kumar S
    Curr Med Chem; 2024; 31(14):1818-1829. PubMed ID: 37013428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems.
    Carnevale D; De Simone R; Minghetti L
    CNS Neurol Disord Drug Targets; 2007 Dec; 6(6):388-97. PubMed ID: 18220778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine and its application in treatment of microglia-mediated neuroinflammation.
    Baby N; Patnala R; Ling EA; Dheen ST
    Curr Med Chem; 2014; 21(37):4215-26. PubMed ID: 25039775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging contributions of formyl peptide receptors to neurodegenerative diseases.
    Busch L; Vieten S; Brödel S; Endres K; Bufe B
    Biol Chem; 2022 Jan; 403(1):27-41. PubMed ID: 34505459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A friend in need may not be a friend indeed: role of microglia in neurodegenerative diseases.
    Kaushik DK; Basu A
    CNS Neurol Disord Drug Targets; 2013 Sep; 12(6):726-40. PubMed ID: 24070095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide.
    Villa V; Thellung S; Bajetto A; Gatta E; Robello M; Novelli F; Tasso B; Tonelli M; Florio T
    Pharmacol Res; 2016 Nov; 113(Pt A):500-514. PubMed ID: 27667770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in therapeutic strategies for microglia-mediated neuroinflammation in neuropathologies.
    Gupta N; Shyamasundar S; Patnala R; Karthikeyan A; Arumugam TV; Ling EA; Dheen ST
    Expert Opin Ther Targets; 2018 Sep; 22(9):765-781. PubMed ID: 30138572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnesium Lithospermate B Suppresses Lipopolysaccharide-Induced Neuroinflammation in BV2 Microglial Cells and Attenuates Neurodegeneration in Lipopolysaccharide-Injected Mice.
    Tai Y; Qiu Y; Bao Z
    J Mol Neurosci; 2018 Jan; 64(1):80-92. PubMed ID: 29196883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ion channels on microglia: therapeutic targets for neuroprotection.
    Skaper SD
    CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):44-56. PubMed ID: 21143139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications.
    Wilms H; Zecca L; Rosenstiel P; Sievers J; Deuschl G; Lucius R
    Curr Pharm Des; 2007; 13(18):1925-8. PubMed ID: 17584117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease.
    Iribarren P; Zhou Y; Hu J; Le Y; Wang JM
    Immunol Res; 2005; 31(3):165-76. PubMed ID: 15888909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders.
    Leitner GR; Wenzel TJ; Marshall N; Gates EJ; Klegeris A
    Expert Opin Ther Targets; 2019 Oct; 23(10):865-882. PubMed ID: 31580163
    [No Abstract]   [Full Text] [Related]  

  • 19. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
    Lipton SA; Gu Z; Nakamura T
    Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.